ZA200604178B - Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity - Google Patents

Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity

Info

Publication number
ZA200604178B
ZA200604178B ZA200604178A ZA200604178A ZA200604178B ZA 200604178 B ZA200604178 B ZA 200604178B ZA 200604178 A ZA200604178 A ZA 200604178A ZA 200604178 A ZA200604178 A ZA 200604178A ZA 200604178 B ZA200604178 B ZA 200604178B
Authority
ZA
South Africa
Prior art keywords
dyslipidemia
obesity
prevention
treatment
pyrazole derivative
Prior art date
Application number
ZA200604178A
Inventor
Arnone Michele
Bensaid Mohammed
Herbert Jean-Marc
Heshmati Hassan Massoud
Janiak Philip
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ZA200604178B publication Critical patent/ZA200604178B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200604178A 2003-10-24 2004-10-22 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity ZA200604178B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0312553A FR2861300B1 (en) 2003-10-24 2003-10-24 USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF METABOLIC SYNDROME

Publications (1)

Publication Number Publication Date
ZA200604178B true ZA200604178B (en) 2008-07-30

Family

ID=34400824

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200604178A ZA200604178B (en) 2003-10-24 2004-10-22 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity

Country Status (4)

Country Link
CN (1) CN1893946A (en)
FR (1) FR2861300B1 (en)
NO (1) NO20062369L (en)
ZA (1) ZA200604178B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102416015B (en) * 2011-08-23 2013-02-27 南京正宽医药科技有限公司 Composition containing statins and application thereof
CN110237070A (en) * 2019-05-10 2019-09-17 辽宁大学 Irbesartan is preparing the application in blood lipid-lowering medicine
CN112007156A (en) * 2019-05-30 2020-12-01 复旦大学 Application of cannabinoid receptor drug in preparation of drug for treating myocardial cell necrotic apoptosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758723B1 (en) * 1997-01-28 1999-04-23 Sanofi Sa USE OF CENTRAL CANNABINOID RECEPTOR ANTAGONISTS FOR THE PREPARATION OF DRUGS
FR2789079B3 (en) * 1999-02-01 2001-03-02 Sanofi Synthelabo PYRAZOLECARBOXYLIC ACID DERIVATIVE, ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
DK1429761T3 (en) * 2001-09-21 2007-02-05 Solvay Pharm Bv New 4,5-dihydro-1H-pyrazole derivatives with CB1 antagonistic effect
CA2478183C (en) * 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
EP1494997A4 (en) * 2002-04-05 2007-04-11 Merck & Co Inc Substituted aryl amides
BR0312503A (en) * 2002-07-09 2007-06-26 Bristol Myers Squibb Co substituted heterocyclic derivatives useful as antidiabetic and anti-obesity agents, pharmaceutical composition, use and combination thereof
US6869966B2 (en) * 2002-09-30 2005-03-22 Banyu Pharmaceutical Co., Ltd. N-substituted-2-oxodihydropyridine derivatives

Also Published As

Publication number Publication date
NO20062369L (en) 2006-05-24
FR2861300A1 (en) 2005-04-29
CN1893946A (en) 2007-01-10
FR2861300B1 (en) 2008-07-11

Similar Documents

Publication Publication Date Title
IL175103A0 (en) Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity
HK1100411A1 (en) Fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
HK1064090A1 (en) Xanthine derivative, production and use thereof asa medicament
IL177914A0 (en) Use of indazolecarboxamide derivatives for the preparation of a medicament that is intended for the treatment and prevention of paludism
IL160524A0 (en) Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity
IL219671A0 (en) 1,2- benzoxazoles and use thereof in the preparation of a medicament
NO2012009I2 (en) Combination product of saxaglipin and metformin and pharmaceutically acceptable salts thereof, including the HCI salts of saxaglipin and metformin
HK1076110A1 (en) Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
EP1534074A4 (en) Combination therapy for the treatment of obesity
ZA200703876B (en) 2-amido -4-phenylthiazole derivatives, the preparation and therapeutic use thereof
ZA200604432B (en) Thiozolidinones production and use thereof as medicaments
IL178903A0 (en) Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
IL184008A0 (en) 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments
HK1074444A1 (en) Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof
GB0207411D0 (en) Azole compounds and their therapeutic use
ZA200604178B (en) Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity
IL177632A0 (en) 2h or 3h-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof
EP1449644A4 (en) Layered product and medical supply comprising the layered product
ZA200608918B (en) Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
EP1485077A4 (en) Drug combination therapy
HK1099689A1 (en) Combination of a heterocyclic compound and an antioxidant and use thereof for the manufacture of a medicament for treating obesity
ZA200704650B (en) 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments
EP1829860A4 (en) 9,10-secopregnane derivative and medicine
IL162125A (en) Use of n-(indolcarbonyl)- piperazine derivatives for the preparation of medicaments for the treatment of obesity
HK1045059A2 (en) Formula for a medicine preparation-spring of ciimacter tablet and the preparation method thereof